Get the Stockscreener App
46.46
0.69%
0.32
After Hours:
46.46
Vaxcyte Inc stock is traded at $46.46, with a volume of 834.75K.
It is up +0.69% in the last 24 hours and up +3.94% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$46.14
Open:
$45.83
24h Volume:
834.75K
Relative Volume:
0.55
Market Cap:
$6.08B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-10.10
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-1.09%
1M Performance:
+3.94%
6M Performance:
+39.65%
1Y Performance:
-44.23%
1-Day Range:
$45.83
$47.76
1-Week Range:
$45.21
$47.76
52-Week Range:
$27.66
$93.77
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
46.46 | 6.04B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Insider Sell Alert: Harpreet Dhaliwal Sells 9,743 Shares of Vaxc - GuruFocus
Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price-Driven Insight from (PCVX) for Rule-Based Strategy - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Nasdaq Composite Tracks Clinical Progress - Kalkine Media
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st
Vaxcyte (NASDAQ:PCVX) Stock Price Up 3.9%Here's Why - MarketBeat
Vaxcyte shows rising price performance with jump to 81 RS rating - MSN
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Vaxcyte Earnings Notes - Trefis
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barron's
What Makes Vaxcyte (PCVX) So Attractive - Finviz
What makes Vaxcyte (PCVX) so attractive - MSN
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Vaxcyte Inc. stock remains resilientJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - Улправда
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Will Vaxcyte Inc. stock keep outperforming rivalsM&A Rumor & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Vaxcyte Inc. stock performs during Fed tightening cyclesDay Trade & Safe Capital Allocation Plans - Улправда
How Vaxcyte Inc. stock performs in rate cut cyclesAnalyst Downgrade & Safe Capital Growth Trade Ideas - Улправда
Vaxcyte Enhances Executive Severance to Align With Market - TipRanks
PCVX (Vaxcyte) EV-to-OCF : -7.70 (As of Dec. 19, 2025) - GuruFocus
Profit Review: Will Vaxcyte Inc. stock attract ESG investorsWeekly Risk Summary & Reliable Intraday Trade Plans - DonanımHaber
Why Vaxcyte Inc. (5VA) stock remains stableTrade Entry Report & AI Powered Trade Plan Recommendations - Улправда
Vaxcyte enhances executive severance to align with market - MSN
Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha
Market Review: Why Vaxcyte Inc stock could benefit from AI revolution2025 Geopolitical Influence & Fast Moving Stock Watchlists - moha.gov.vn
Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors - Yahoo Finance
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension - MSN
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
Vaxcyte (PCVX) Gets a Buy from Guggenheim - The Globe and Mail
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com Canada
Vaxcyte Finalizes Trial Design for VAX-31, Aiming to Set New Standard for Adult Pneumococcal Vaccines in Consultation with FDA - Quiver Quantitative
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):